CytoNiche
Latest round
- Series B
Last raised
- Sep 2025
Total raised
- $47M
Investors
- 22
About CytoNiche
Founded in 2018, CytoNiche is focused on the development of advanced technologies in 3D cell manufacturing. The company has not reported any significant pivots or changes in its business strategy. It is headquartered in Beijing, China, and was co-founded by Wei Liu and Xiaojun Yan, both of whom serve as its CEOs. CytoNiche specializes in developing a 3D cell manufacturing platform aimed at the cell and gene therapy sectors. Their core offerings include advanced technology services that facilitate scalable three-dimensional cell amplification, addressing critical manufacturing challenges. The company serves biopharmaceutical firms and research institutions, with a focus on innovative treatment modalities, and markets its products in North America, Europe, and Asia. CytoNiche operates a revenue model based on providing specialized technical services to the biopharmaceutical industry. Their transactions primarily involve B2B partnerships where companies contract CytoNiche for expertise in 3D cell manufacturing processes, leading to tailored service agreements that meet specific therapeutic goals.
Who invested in CytoNiche
22 investors across 5 rounds
See all investors in CytoNiche
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about CytoNiche
Who invested in CytoNiche?
CytoNiche has 22 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has CytoNiche raised?
CytoNiche has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did CytoNiche last raise money?
CytoNiche's most recent round on record is a Series B, in Sep 2025.
What does CytoNiche do?
Founded in 2018, CytoNiche is focused on the development of advanced technologies in 3D cell manufacturing.
Where is CytoNiche headquartered?
CytoNiche is headquartered in Beijing, China.
Which VCs invest in companies like CytoNiche?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at CytoNiche's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like CytoNiche? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.